End-stage diseases of the hip joint
Conditions
Interventions
Intraosseous injection group:All subjects were given intramedullary injections of tranexamic acid at 20 mg/kg according to the patients body weight at the following sites: lateral aspect of the greate
intravenous group:All subjects were given tranexamic acid intravenously at 20 mg/kg based on the patients body weight 0.5 hours before skin incision
Local injection group:Tranexamic acid was administered locally according to the patients body weight (20 mg/kg) before suturing the surgical area.
blank control group:Tranexamic acid is not given
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Age =18 years and gender; (2) Patients diagnosed with end-stage hip diseases such as severe ischaemic necrosis of the femoral head, osteoarthritis of the hip, and developmental hip dislocation according to the American Academy of Orthopaedic Surgeons treatment guidelines. (3) Undergoing initial unilateral total hip arthroplasty; (4) Voluntary and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Hypersensitivity to tranexamic acid; (2) Previous history of thromboembolism (including lower extremity deep vein thromboembolism, pulmonary embolism, cerebral infarction, transient ischaemic attack, myocardial infarction or angina attack within 6 months); (3) Progressive renal insufficiency (stage 4 and above) or glomerular filtration rate less than 30 ml/min; (4) Congenital or acquired coagulation disorders; (5) Prolonged use of anticoagulants or antiplatelet agents for other medical conditions (with the exception of routine perioperative anticoagulation by receiving a single subcutaneous injection of low molecular heparin sodium 40mg 12 hours prior to surgery and 12 hours postoperatively); (6) Preoperative assessment of American Society of Anaesthesiologists (ASA) level 4 (7) Preoperative prothrombin time (PT) international normalised ratio (INR) >1.4. (8) Needing radiotherapy or chemotherapy for oncological diseases; (9) Severe immunodeficiency diseases (e.g. stage 3 HIV, sickle cell anaemia, splenectomy, etc.) (10) Previous history of substance abuse; (11) Use of immunosuppressive drugs for bone marrow or other grafts; (12) Pregnant, maternal and breastfeeding women; (13) Patients with acquired visual defects; (14) Patients with a history of convulsions; (15) Participating in other clinical trials; (16) Persons who, in the opinion of the investigator, are otherwise unsuitable for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative haemoglobin reduction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative blood loss;Postoperative blood transfusion rate, volume;Length of postoperative hospital stay;Changes in the amount of drainage in the operative area;Incidence of postoperative lower limb venous thrombosis;Measurement of inflammatory markers in peripheral blood; | — |
Countries
China
Contacts
Public ContactCao Li
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed